Clinical Trial Update: A Prospective, Single-Arm, Phase II Clinical Study of Neoadjuvant Therapy With Pucotenlimab, Lenvatinib, and Temozolomide for Resectable Head and Neck Mucosal Melanoma (PLT-NAT-HNMM-II) [Phase 2]

View source ↗

Summary

A prospective, single-arm Phase II study evaluating neoadjuvant pucotenlimab with lenvatinib and temozolomide for resectable head and neck mucosal melanoma; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucosal Melanoma of the Head and Neck

Drugs mentioned

• LENVIMA (lenvatinib)
• Pucotenlimab
• Temodar (Temozolomide)

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Head and Neck Mucosal Melanomas | Phase 2 | Status: NOT_YET_RECRUITING